Partial atrophy on prostate needle biopsy cores: A morphologic and immunohistochemical study

Wenle Wang, Xinlai Sun, Jonathan Ira Epstein

Research output: Contribution to journalArticle

Abstract

Partial atrophy is the most common benign mimicker of prostate cancer on needle biopsy. Of 3916 prostate needle core biopsy cases received in our consultation service over a period of 3 months (March 1, 2007 to May 31, 2007), 170 cases (4.3%) with partial atrophy were diagnosed as atypical glands by outside pathologists and prospectively identified. We supplemented our material with 108 cases of partial atrophy sent to our consultation service in 2006 from a single institution, which frequently uses a triple cocktail stain [p63, high molecular weight cytokeratin (HMWCK), α-methyl acyl-Coa racemase (AMACR)]. The morphologic features of the 278 cases and immunohistochemistry of 236 cases (198 with prostate cocktail and 38 with only basal cell makers) were an lyzed. Forty-eight of 278 (17.3%) partial atrophy cases were mixed with postatrophic hyperplasia. Enlarged nuclei were visible in 43/278 (15.5%) cases, with prominent nucleoli seen in 58/278 (20.9%) cases (30 cases associated with nuclear enlargement). Of 198 cases with a prostatic cocktail stain, 48 (24.2%) had a cancer pattern for both basal cells and AMACR (p63-, HMWCK-, and AMACR+), 14 (7.1%) had a cancer pattern for basal cells (p63-, HMWCK-, and AMACR-), 89 (44.9%) had a cancer pattern for AMACR (p63+, HMWCK+, and AMACR+), and 47 (23.7%) had a totally benign pattern (p63+, HMWCK+, and AMACR-). Of the 198 cases using the cocktail stain, 136 (68.7%) had positive basal cell staining. The percentage of basal cells labeled with the combination of p63/HMWCK was: 75% in 36 (18.2%) cases. An additional 38 cases immunostained only for p63 and/or HMWCK was negative in 2 (5.2%) cases, 75% in 12 (31.6%) cases. In conclusion, partial atrophy is a benign mimicker of adenocarcinoma both as a result of its routine morphologic features and its immunohistochemical profile. Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)851-857
Number of pages7
JournalAmerican Journal of Surgical Pathology
Volume32
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Large-Core Needle Biopsy
Atrophy
Keratins
Prostate
Molecular Weight
Coloring Agents
Basal Cell Neoplasms
Adenocarcinoma
Referral and Consultation
Keratin-14
Racemases and Epimerases
Needle Biopsy
Hematoxylin
Eosine Yellowish-(YS)
Diagnostic Errors
Hyperplasia
Neoplasms
Prostatic Neoplasms
Immunohistochemistry
Staining and Labeling

Keywords

  • Adenocarcinoma
  • AMACR
  • Atrophy
  • High molecular weight cytokeratin
  • Immunohistochemistry
  • P63
  • Partial atrophy
  • Prostate

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery
  • Medicine(all)

Cite this

Partial atrophy on prostate needle biopsy cores : A morphologic and immunohistochemical study. / Wang, Wenle; Sun, Xinlai; Epstein, Jonathan Ira.

In: American Journal of Surgical Pathology, Vol. 32, No. 6, 06.2008, p. 851-857.

Research output: Contribution to journalArticle

@article{b983d332e86845df9d9162961cb15e8a,
title = "Partial atrophy on prostate needle biopsy cores: A morphologic and immunohistochemical study",
abstract = "Partial atrophy is the most common benign mimicker of prostate cancer on needle biopsy. Of 3916 prostate needle core biopsy cases received in our consultation service over a period of 3 months (March 1, 2007 to May 31, 2007), 170 cases (4.3{\%}) with partial atrophy were diagnosed as atypical glands by outside pathologists and prospectively identified. We supplemented our material with 108 cases of partial atrophy sent to our consultation service in 2006 from a single institution, which frequently uses a triple cocktail stain [p63, high molecular weight cytokeratin (HMWCK), α-methyl acyl-Coa racemase (AMACR)]. The morphologic features of the 278 cases and immunohistochemistry of 236 cases (198 with prostate cocktail and 38 with only basal cell makers) were an lyzed. Forty-eight of 278 (17.3{\%}) partial atrophy cases were mixed with postatrophic hyperplasia. Enlarged nuclei were visible in 43/278 (15.5{\%}) cases, with prominent nucleoli seen in 58/278 (20.9{\%}) cases (30 cases associated with nuclear enlargement). Of 198 cases with a prostatic cocktail stain, 48 (24.2{\%}) had a cancer pattern for both basal cells and AMACR (p63-, HMWCK-, and AMACR+), 14 (7.1{\%}) had a cancer pattern for basal cells (p63-, HMWCK-, and AMACR-), 89 (44.9{\%}) had a cancer pattern for AMACR (p63+, HMWCK+, and AMACR+), and 47 (23.7{\%}) had a totally benign pattern (p63+, HMWCK+, and AMACR-). Of the 198 cases using the cocktail stain, 136 (68.7{\%}) had positive basal cell staining. The percentage of basal cells labeled with the combination of p63/HMWCK was: 75{\%} in 36 (18.2{\%}) cases. An additional 38 cases immunostained only for p63 and/or HMWCK was negative in 2 (5.2{\%}) cases, 75{\%} in 12 (31.6{\%}) cases. In conclusion, partial atrophy is a benign mimicker of adenocarcinoma both as a result of its routine morphologic features and its immunohistochemical profile. Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma.",
keywords = "Adenocarcinoma, AMACR, Atrophy, High molecular weight cytokeratin, Immunohistochemistry, P63, Partial atrophy, Prostate",
author = "Wenle Wang and Xinlai Sun and Epstein, {Jonathan Ira}",
year = "2008",
month = "6",
doi = "10.1097/PAS.0b013e31815a0508",
language = "English (US)",
volume = "32",
pages = "851--857",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Partial atrophy on prostate needle biopsy cores

T2 - A morphologic and immunohistochemical study

AU - Wang, Wenle

AU - Sun, Xinlai

AU - Epstein, Jonathan Ira

PY - 2008/6

Y1 - 2008/6

N2 - Partial atrophy is the most common benign mimicker of prostate cancer on needle biopsy. Of 3916 prostate needle core biopsy cases received in our consultation service over a period of 3 months (March 1, 2007 to May 31, 2007), 170 cases (4.3%) with partial atrophy were diagnosed as atypical glands by outside pathologists and prospectively identified. We supplemented our material with 108 cases of partial atrophy sent to our consultation service in 2006 from a single institution, which frequently uses a triple cocktail stain [p63, high molecular weight cytokeratin (HMWCK), α-methyl acyl-Coa racemase (AMACR)]. The morphologic features of the 278 cases and immunohistochemistry of 236 cases (198 with prostate cocktail and 38 with only basal cell makers) were an lyzed. Forty-eight of 278 (17.3%) partial atrophy cases were mixed with postatrophic hyperplasia. Enlarged nuclei were visible in 43/278 (15.5%) cases, with prominent nucleoli seen in 58/278 (20.9%) cases (30 cases associated with nuclear enlargement). Of 198 cases with a prostatic cocktail stain, 48 (24.2%) had a cancer pattern for both basal cells and AMACR (p63-, HMWCK-, and AMACR+), 14 (7.1%) had a cancer pattern for basal cells (p63-, HMWCK-, and AMACR-), 89 (44.9%) had a cancer pattern for AMACR (p63+, HMWCK+, and AMACR+), and 47 (23.7%) had a totally benign pattern (p63+, HMWCK+, and AMACR-). Of the 198 cases using the cocktail stain, 136 (68.7%) had positive basal cell staining. The percentage of basal cells labeled with the combination of p63/HMWCK was: 75% in 36 (18.2%) cases. An additional 38 cases immunostained only for p63 and/or HMWCK was negative in 2 (5.2%) cases, 75% in 12 (31.6%) cases. In conclusion, partial atrophy is a benign mimicker of adenocarcinoma both as a result of its routine morphologic features and its immunohistochemical profile. Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma.

AB - Partial atrophy is the most common benign mimicker of prostate cancer on needle biopsy. Of 3916 prostate needle core biopsy cases received in our consultation service over a period of 3 months (March 1, 2007 to May 31, 2007), 170 cases (4.3%) with partial atrophy were diagnosed as atypical glands by outside pathologists and prospectively identified. We supplemented our material with 108 cases of partial atrophy sent to our consultation service in 2006 from a single institution, which frequently uses a triple cocktail stain [p63, high molecular weight cytokeratin (HMWCK), α-methyl acyl-Coa racemase (AMACR)]. The morphologic features of the 278 cases and immunohistochemistry of 236 cases (198 with prostate cocktail and 38 with only basal cell makers) were an lyzed. Forty-eight of 278 (17.3%) partial atrophy cases were mixed with postatrophic hyperplasia. Enlarged nuclei were visible in 43/278 (15.5%) cases, with prominent nucleoli seen in 58/278 (20.9%) cases (30 cases associated with nuclear enlargement). Of 198 cases with a prostatic cocktail stain, 48 (24.2%) had a cancer pattern for both basal cells and AMACR (p63-, HMWCK-, and AMACR+), 14 (7.1%) had a cancer pattern for basal cells (p63-, HMWCK-, and AMACR-), 89 (44.9%) had a cancer pattern for AMACR (p63+, HMWCK+, and AMACR+), and 47 (23.7%) had a totally benign pattern (p63+, HMWCK+, and AMACR-). Of the 198 cases using the cocktail stain, 136 (68.7%) had positive basal cell staining. The percentage of basal cells labeled with the combination of p63/HMWCK was: 75% in 36 (18.2%) cases. An additional 38 cases immunostained only for p63 and/or HMWCK was negative in 2 (5.2%) cases, 75% in 12 (31.6%) cases. In conclusion, partial atrophy is a benign mimicker of adenocarcinoma both as a result of its routine morphologic features and its immunohistochemical profile. Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma.

KW - Adenocarcinoma

KW - AMACR

KW - Atrophy

KW - High molecular weight cytokeratin

KW - Immunohistochemistry

KW - P63

KW - Partial atrophy

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=46249105575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249105575&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e31815a0508

DO - 10.1097/PAS.0b013e31815a0508

M3 - Article

C2 - 18408595

AN - SCOPUS:46249105575

VL - 32

SP - 851

EP - 857

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 6

ER -